Creation of Straight-Chain Cationic Polysaccharide-Based Bile Salt Sequestrants Made from Euglenoid β-1,3-Glucan as Potential Antidiabetic Agents
Straight-chain polysaccharides have a greater potential of selectively adsorbing hydrophobic bile salts than resin-based bile salt sequesters because of ionic and hydrophobic interactions; hence, they may possess antidiabetic activity. The feasibility of using cationic polysaccharides made from euglenoid β-1,3-glucan (referred to as paramylon) as potential antidiabetic agents was examined by using in vitro and animal experiments.
Cationic straight-chain polysaccharides were synthesized from euglenoid polysaccharide and glycidyltrimethylammonium chloride. The effects of administration of the synthetic polysaccharide on metabolic syndrome-related indicators were examined in high-fat diet-induced obesity mice. The degree of adsorption of bile salts by the polysaccharides was evaluated using spectroscopic analysis.
Administration of the cationic paramylon derivatives significantly reduced body and mesenteric fat weight in high-fat diet-induced obesity mice. A noteworthy effect was that glucagon-like peptide-1 (GLP-1) secretion was approximately three times higher in diet-induced obesity mice receiving cationic paramylon derivatives than in those receiving cellulose as a control.
Our results indicate that these cationic paramylon derivatives are potential GLP-1 secretagogues suitable for further study.
Key Wordsantidiabetic agent bile salt sequestrants GLP-1 polysaccharide
Anionic exchange resin
Degree of substitution
DS of the 2-hydroxy-3-(trimethylammonio)propyl group
Size exclusion chromatography - multi-angle laser light scattering
- 3.Sugimoto-Kawabata K, Shimada H, Sakai K, Suzuki K, Kelder T, Pieterman EJ, et al. Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. J Lipid Res. 2013;54(5):1255–64.Google Scholar
- 5.Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep. 2012;2:430.Google Scholar
- 6.Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013;304(4):G371–G80.Google Scholar
- 8.Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91(5):1916–23.Google Scholar
- 9.Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Phys. 1997;273(5 Pt 1):E981–8.Google Scholar
- 10.Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435–40.Google Scholar
- 12.Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (Cholestagel) - a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159(16):1893–900.Google Scholar
- 16.Kazlauske J, Ramanauskiene K, Liesiene J. Binding of bile acids by cellulose-based cationic adsorbents. Cell Chem Technol. 2014;48(1–2):11–7.Google Scholar
- 18.Barras DR, Stone BA. Carbohydrate composition and metabolism. In: Buetow DE, editor. The biology of Euglena, vol. II. New York: Academic Press; 1968. p. 149–87.Google Scholar
- 24.Hung SC, Bartley G, Young SA, Albers DR, Dielman DR, Anderson WH, et al. Dietary fiber improves lipid homeostasis and modulates adipocytokines in hamsters. J Diabetes. 2009;1(3):194–206.Google Scholar
- 26.Doubilet H. Differential quantitative analysis of bile acids in bile and in duodenal drainage. J Biol Chem. 1936;114(1):289–308.Google Scholar
- 28.Findlay JBC, Evans WH. Biological membranes: a practical approach. Washington DC: IRL Press; 1987.Google Scholar
- 29.Detergents NJM. An overview. In: Deutscher MP, editor. Methods in enzymology. Massachusetts: Academic Press; 1990. p. 239–53.Google Scholar
- 30.Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology. 2010;51(3):806–16.Google Scholar
- 31.Benson GM, Alston DR, Bond BC, Gee AN, Glen A, Haynes C, et al. F 97426-a a more potent bile acid sequestrant and hypocholesterolaemic agent than cholestyramine in the hamster. Atherosclerosis. 1993;101(1):51–60.Google Scholar
- 33.Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damçi T, Liebl A, et al. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab. 2011;96(11):3337–53.Google Scholar
- 35.Chen L, McNulty J, Anderson D, Liu Y, Nystrom C, Bullard S, et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther. 2010;334(1):164–70.Google Scholar
- 36.Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298(5):714–9.Google Scholar
- 38.Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, et al. Novel potent and selective bile acid derivatives as TGR5 agonists:biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008;51(6):1831–41.Google Scholar
- 39.Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489–94.Google Scholar